AKT1 and Miyoshi myopathy: Two-drug combinations that target MAPK and PI3K/Akt signaling pathways in parallel impart synergistic inhibition of tumor growth and metastasis in mouse models of MM with Ras/MAPK and PI3K/AKT/mTOR activation [32,49].